Key facts
- This page summarizes Marshall S. Stanton's Form 4 filing for ARTIVION, INC. (AORT).
- 8 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 24 Nov 2025, 17:23.
Marshall S. Stanton - 21 Nov 2025 Form 4 Insider Report for ARTIVION, INC. (AORT)
- Reporting relationship
- SVP, Clinical & MD Affair
- Issuer ticker
- AORT
- Reported as of
- 21 Nov 2025
- Net transaction value
- -$1,460,932
- SEC form
- 4
- Accepted by SEC
- 24 Nov 2025, 17:23:45 UTC
- Prior SEC filing
- 24 Nov 2025
- Next SEC filing
- 28 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Marshall Stanton
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Marshall S. Stanton filed Form 4 for ARTIVION, INC. (AORT) on 24 Nov 2025.
Change
- Previous filing in this sequence was filed on 24 Nov 2025.
- Current net transaction value: -$1,460,932.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001849615
Primary reporting owner
Stanton Marshall S.
- Relationship
- SVP, Clinical & MD Affair
- Address
- 1655 ROBERTS BLVD., NW, KENNESAW
- Signature
- /s/ Marshall Stanton
- Signature date
- 24 Nov 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AORT
transaction
Common Stock
Options Exercise
- Transaction value
- $374,350
- Shares
- +20,301
- Change %
- +45%
- Price
- $18.44
- Shares after
- 65,054
- Date
- 21 Nov 2025
- Ownership
- Direct
AORT
transaction
Common Stock
Sale
- Transaction value
- $655,189
- Shares
- -14,586
- Change %
- -22%
- Price
- $44.92
- Shares after
- 50,468
- Date
- 21 Nov 2025
- Ownership
- Direct
- Footnotes
- F1
AORT
transaction
Common Stock
Sale
- Transaction value
- $259,152
- Shares
- -5,715
- Change %
- -11%
- Price
- $45.35
- Shares after
- 44,753
- Date
- 21 Nov 2025
- Ownership
- Direct
- Footnotes
- F2
AORT
transaction
Common Stock
Options Exercise
- Transaction value
- $298,637
- Shares
- +27,075
- Change %
- +60%
- Price
- $11.03
- Shares after
- 71,828
- Date
- 21 Nov 2025
- Ownership
- Direct
AORT
transaction
Common Stock
Sale
- Transaction value
- $840,042
- Shares
- -18,705
- Change %
- -26%
- Price
- $44.91
- Shares after
- 53,123
- Date
- 21 Nov 2025
- Ownership
- Direct
- Footnotes
- F3
AORT
transaction
Common Stock
Sale
- Transaction value
- $379,538
- Shares
- -8,370
- Change %
- -16%
- Price
- $45.34
- Shares after
- 44,753
- Date
- 21 Nov 2025
- Ownership
- Direct
- Footnotes
- F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AORT
transaction
Derivative
Stock Options (Right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -20,301
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 21 Nov 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,301
- Exercise price
- $18.44
- Footnotes
- F5
AORT
transaction
Derivative
Stock Options (Right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -27,075
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 21 Nov 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 27,075
- Exercise price
- $11.03
- Footnotes
- F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
Reflects weighted average price. Range of prices were between $44.26 to $45.25. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Footnote F2
Reflects weighted average price. Range of prices were between $45.26 to $45.54. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Footnote F3
Reflects weighted average price. Range of prices were between $44.26 to $45.255. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Footnote F4
Reflects weighted average price. Range of prices were between $45.26 to $45.53. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Footnote F5
Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was February 23, 2023.
Footnote F6
Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was November 8, 2023.